Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$97.33 USD

97.33
648,582

+0.07 (0.07%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $97.39 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why Investors Should Buy Luminex (LMNX) Right Now

The market is upbeat about Luminex's (LMNX) recent partnership with Sutter Health and FDA approvals.

    Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod

    Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest U.K. national reimbursement grant.

      Fresenius Medical Opens Manufacturing Plant in Malaysia

      Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.

        Amedisys Rides High on Strong Prospects Amid Margin Woes

        Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.

          Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm

          Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.

            IDEXX Laboratories Rides High on Strong CAG, Global Growth

            IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.

              Medtronic Launches StealthStation Technology, Expands in ENT

              Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.

                AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                AmerisourceBergen Corporation's (ABC) expects tepid performance from PharMEDium due to pricing pressure in the generic drug space.

                  CVS Health Gains on Pharmacy Services, Retail Remains a Drag

                  CVS Health (CVS) benefits from strong Pharmacy Services numbers and continues to deliver solid PBM selling seasons. Retail performance stays sluggish on several headwinds.

                    Medtronic (MDT) Begins Product Recall, Diabetes Group a Drag

                    Medtronic (MDT) decides to recall specific lots of insulin pumps in peril. The devices appear to potentially over-deliver insulin exposing patients to chances of hypoglycemia.

                      5 Discounted MedTech Stocks for a Healthy Portfolio

                      In view of the current political scenario and banking on favorable metrics, these five MedTech stocks stand out as the most suitable value picks.

                        Becton, Dickinson's (BCR) C.R. Bard Buyout Plans Bode Well

                        Becton, Dickinson and Company's (BDX) steady move toward the pending acquisition of C.R. Bard will lend it a leading position in the healthcare domain.

                          Zimmer Biomet (ZBH) Launches Persona Partial Knee System

                          Zimmer Biomet (ZBH) is constantly trying to turn its Knees business around. Keeping in line with the efforts, the company has launched Persona Partial Knee System.

                            Top Ranked Growth Stocks to Buy for September 12th

                            Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, September 12th:

                              Ecolab (ECL) Features in DJSI List for Third Consecutive Year

                              Ecolab???s (ECL) nomination as a leading player in the Dow Jones Sustainability Index will lend the company a leading position in the healthcare domain.

                                Henry Schein MicroMD Software Gets ONC-Health IT Certificate

                                Henry Schein's (HSIC) MicroMD receives ONC-Health IT Certificate from Drummond Group, boosting the company's technology and value-added service business.

                                  Chemed Rides on VITAS Recovery, Robust Roto-Rooter Sales

                                  Chemed (CHE) steers growth with VITAs business' revival from struggle and Roto-Rooter's consistent rise on the back of core plumbing and drain cleaning service segments.

                                    NuVasive Grows in Pediatric Deformity With New FDA Approval

                                    NuVasive (NUVA) has progressed with its 'Embracing the Journey Together' program with the FDA nod to use the company's redesigned MAGEC system with its RELINE Small Stature system.

                                      Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

                                      Abbott's (ABT) recent FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device has boosted investor confidence.

                                        8 Factors That Make Thermo Fisher a Valuable Pick Right Now

                                        Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

                                          Cooper to Benefit From Specialty Lenses Prospects Amid Woes

                                          The Cooper Companies' (COO) strong sales growth will continue to be aided by a leading position in the market of specialty lenses.

                                            Align Technology at 52-Week High: What's Driving the Stock?

                                            Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.

                                              Boston Scientific Grows on Innovation, Buyouts Amid Woes

                                              While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.

                                                Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite

                                                Myriad Genetics (MYGN) introduces riskScore, a breast cancer prediction tool to broaden its myRisk hereditary cancer test offerings.

                                                  HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates

                                                  HealthEquity (HQY) delivered favorable results in the second quarter of fiscal 2018 on the back of revenue and margin expansion.